查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984208

非侵入性液态生物检体市场：按技术、生物标记、检体类型、应用和最终用户划分－2026-2032年全球市场预测

Non-Invasive Liquid Biopsy Market by Technology, Biomarker, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，非侵入性液态生物检体市场价值将达到 52.8 亿美元，到 2026 年将成长至 57.7 亿美元，到 2032 年将达到 98.4 亿美元，年复合成长率为 9.29%。

主要市场统计数据
基准年 2025 52.8亿美元
预计年份：2026年 57.7亿美元
预测年份 2032 98.4亿美元
复合年增长率 (%) 9.29%

本文全面说明了非侵入性、以液体为基础的分子诊断如何过渡到主流临床工作流程和精准医疗范式。

非侵入性液态生物检体正迅速从小众研究工具发展成为基础临床诊断方法，革新了生物讯号的收集、解读和应用方式。核酸检测、先进定序和高灵敏度数位定量技术的创新推动了这一发展，使临床医生和研究人员能够从週边血液和其他体液中获取可操作的分子资讯。因此，传统的切片检查正逐渐被基于体液的检测方法所取代，后者俱有降低患者风险、可重复采样以及早期疗育的潜力等优点。

本报告从多方面检验了技术进步、监管变革和经营模式的融合，这些融合正在重新定义非侵入性诊断和临床应用的途径。

非侵入性液态生物检体领域正经历着一场变革性的转变，这场转变是由技术、监管和临床动态的融合所驱动的，它全面重塑了检测、解读和后续治疗的路径。首先，次世代定序化学、误差抑制技术和数位定量技术的进步，显着提升了分析能力，扩大了可侦测讯号的范围，从而能够更早发现疾病并更可靠地监测微量残存疾病。这些技术进步与生物资讯学的成熟相辅相成，机器学习驱动的变异检测和多成分融合方法提高了特异性并降低了假阳性率。

对计划于 2025 年进行的美国关税调整将如何影响整个诊断生态系统的供应链、筹资策略和製造地进行策略分析。

美国宣布将于2025年调整关税，其累积影响正造成商业性和营运方面的复杂性，相关人员必须积极应对。影响诊断设备、定序耗材和特殊试剂的关税措施可能会改变平台提供者和检查室网路的接收成本。为此，製造商正努力修订筹资策略、优化材料清单(BOM) 并审查关税分类，以在维持供应链连续性的同时，最大限度地减少成本波动。

透过对多维细分进行全面整合，揭示技术、应用、生物标记和最终用户方面的差异如何影响产品的适用性和临床应用。

细分市场分析揭示了技术选择、临床应用、生物标记标靶和终端用户群体如何共同决定液态生物检体解决方案的价值提案和应用路径。技术细分区分了数位PCR平台（包括各种束流式和液滴式数位PCR）与涵盖标靶定序、全EXOME序和全基因组定序的次世代定序方法。同时，定量PCR仍然是成熟检测方法的常用选择。每种技术系列在灵敏度、通量和成本结构方面各有侧重，了解这些权衡对于使检测设计与临床目标相符至关重要。

从地理平衡的观点解释区域法规结构、偿还环境和基础设施成熟度如何决定全球市场商业化的轨迹。

区域趋势对策略至关重要，因为独特的管理体制、报销系统和医疗基础设施决定了它们如何影响液态生物检体解决方案的推广。在美洲，整合的医疗体系和私人实验室网路能够实现快速的临床检验和广泛的保险谈判，这往往推动了临床创新，而官民合作关係进一步推进了人群筛检试点计画和肿瘤治疗路径。在欧洲、中东和非洲，监管协调工作和国家医疗技术评估流程呈现出碎片化的特点，需要量身定制的证据包和区域性的商业策略。集中化的监理合作和区域采购机制也常常影响市场进入的顺序。

一份精闢的竞争分析报告，揭示了垂直整合、伙伴关係框架和技术差异化如何推动产业内企业的策略定位。

对主要企业的分析表明，策略定位、能力整合和伙伴关係关係是决定竞争优势的主要因素。成熟的仪器製造商通常会利用其现有的仪器基础设施和服务网路来加速新检测方法的推广应用，而定序平台提供者则在通量、误差控制和生态系统支援（例如文库构建试剂盒和云端分析）方面竞争。诊断试剂盒和试剂供应商专注于其供应链中可靠且可重复的生产流程，而专业的生物资讯公司则透过专有的变异检测技术、多样检体融合演算法以及简化终端用户解读的临床报告工作流程来脱颖而出。

一系列可操作的、优先排序的策略建议，旨在帮助产业领导者协调技术开发、证据生成和商业性实施，以实现永续成长。

针对行业领导者的实际建议着重于使产品开发与临床需求保持一致，增强供应链韧性，并优先创建能够引起保险公司和指南制定机构共鸣的证据。製造商应逐步投资于模组化设计，以便在关税和物流挑战出现时能够轻鬆进行组件替换和在地采购，从而在短期供应和长期平台扩充性之间取得平衡。同时，企业需要投资于全面的临床检验项目，以证明产品在早期检测和微量残存疾病（MRD）等目标适应症中具有显着的临床效用，并设计能够反映常规临床工作流程的可操作性临床试验。

我们透明且可重复的研究框架，结合了与关键相关人员的互动、同行评审证据的整合以及情境分析，从而得出可靠的策略结论。

本调查方法整合了多方面的证据收集、严格的检验和迭代整合，以确保研究结果既反映技术现状，也反映临床实践。主要资料输入结合了检查室管理人员、临床研究人员和行业高管的结构化访谈，以及对同行评审的临床研究、监管申报文件和会议报告的分析，从而全面检验检测方法的性能和临床效用。次要研究则透过梳理技术进步、供应链结构和区域法规结构，补充并阐释这些研究结果的策略意义。

一项具有前瞻性的综合分析，将技术成熟度、证据要求和营运策略与透过液态生物检体创新可实现的临床影响联繫起来。

总之，非侵入液态生物检体正处于一个转折点，技术成熟、证据累积和经营模式不断演进在此交汇，创造了巨大的临床机会。随着检测灵敏度和分析能力的提升，曾经的设想正逐步转化为现实的临床应用，尤其是在肿瘤学、感染疾病监测和产前筛检。然而，成功需要技术开发人员、检查室营运者、保险公司和监管机构之间的密切合作，以确保产生充分的证据、明确临床工作流程并实现经济高效的实施。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 非侵入性液态生物检体市场：依技术划分

  • 数位PCR
    • BEAMing
    • 液滴式数位PCR
  • 次世代定序
    • 目标序列
    • 全EXOME定序
    • 全基因组定序
  • 定量PCR

第九章 生物标记分类的非侵入性液态生物检体市场

  • 细胞中的游离DNA
  • 循环肿瘤DNA
  • 外泌体

第十章检体类型分類的非侵入性液态生物检体市场

  • 航班
  • 尿
  • 唾液

第十一章 非侵入性液态生物检体市场：按应用领域划分

  • 癌症筛检
    • 早期检测
    • 微量残存疾病的监测
  • 感染疾病诊断
  • 产前检查
    • 染色体异常筛检
    • 单基因疾病筛检

第十二章 非侵入性液态生物检体市场：依最终用户划分

  • 私人考试机构
  • 医院检查室
  • 研究机构

第十三章 非侵入性液态生物检体市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 非侵入性液态生物检体市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 非侵入性液态生物检体市场：按国家/地区划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国非侵入性液态生物检体市场

第十七章：中国无创液态生物检体市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Angle PLC
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Biocept, Inc.
  • DiaCarta, Inc.
  • Epic Sciences Inc.
  • F. Hoffmann-La Roche Ltd.
  • Grail, Inc.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Integrated DNA Technologies, Inc.
  • Laboratory Corporation of America Holdings
  • Lonza Group Ltd.
  • Lucence Diagnostics Pte. Ltd.
  • LungLife AI, Inc.
  • Mdxhealth BV
  • MedGenome Labs Ltd.
  • Menarini Silicon Biosystems SpA
  • Merck KGaA
  • Natera, Inc.
  • Nonacus Limited
  • Norgen Biotek Corporation
  • Oasis Diagnostics Corporation
  • OraSure Technologies, Inc
  • QIAGEN GmbH
  • Thermo Fisher Scientific Inc.
  • Zymo Research Corp.
Product Code: MRR-5C6F41F5B02E

The Non-Invasive Liquid Biopsy Market was valued at USD 5.28 billion in 2025 and is projected to grow to USD 5.77 billion in 2026, with a CAGR of 9.29%, reaching USD 9.84 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.28 billion
Estimated Year [2026] USD 5.77 billion
Forecast Year [2032] USD 9.84 billion
CAGR (%) 9.29%

An integrated overview explaining how non-invasive fluid-based molecular diagnostics are transitioning into mainstream clinical workflows and precision medicine paradigms

Non-invasive liquid biopsy is rapidly evolving from a niche research tool into a foundational clinical diagnostic approach that reshapes how biological signals are captured, interpreted, and applied. This evolution is driven by innovations in nucleic acid detection, advanced sequencing, and sensitive digital quantitation, which together enable clinicians and researchers to obtain actionable molecular information from peripheral blood and other bodily fluids. As a result, the traditional reliance on tissue biopsies is progressively complemented by fluid-based assays that offer reduced patient risk, repeatable sampling over time, and the potential for earlier intervention.

In practice, liquid biopsy workflows intersect laboratory science, bioinformatics, and clinical decision-making. Diagnostic sensitivity improvements and biomarker discovery have broadened clinical utility beyond oncology into infectious disease surveillance and prenatal screening, thereby increasing cross-disciplinary adoption. Moreover, the integration of robust informatics pipelines has converted raw assay signals into clinically meaningful outputs, accelerating translational pathways and fostering payer conversations.

Consequently, stakeholders across healthcare-platform developers, clinical laboratories, hospital systems, payers, and regulators-face a collective imperative to adapt governance, reimbursement frameworks, and operational models. As such, this introduction frames liquid biopsy not merely as an incremental diagnostic advancement but as a systemic enabler of precision medicine that requires coordinated investment in technology, evidence generation, and ecosystem alignment.

A nuanced examination of converging technological gains, regulatory shifts, and commercial models that are redefining non-invasive diagnostics and clinical adoption pathways

The landscape of non-invasive liquid biopsy is undergoing transformative shifts driven by converging technological, regulatory, and clinical dynamics that collectively redefine detection, interpretation, and downstream care pathways. First, analytic performance gains- propelled by improvements in next-generation sequencing chemistry, error suppression methods, and digital quantitation-have expanded detectable signal windows, enabling earlier disease detection and more reliable minimal residual disease monitoring. These technical advances are complemented by bioinformatics maturation, where machine learning-enhanced variant calling and multi-analyte fusion approaches increase specificity and reduce false positives.

At the same time, clinical adoption curves are being reshaped by accumulating real-world evidence and consensus guideline updates that validate certain liquid biopsy applications. Payers are increasingly receptive when clinical utility is demonstrated through prospective studies and cost-effectiveness analyses, which in turn incentivizes wider clinical uptake. Meanwhile, commercial strategies are shifting from single-assay propositions toward platform-centric offerings that bundle hardware, consumables, and analytics into subscription or service models, thereby lowering entry barriers for end users.

Finally, supply chain resilience and global partnerships are influencing strategic decisions; manufacturers are diversifying sourcing and pursuing regional manufacturing footholds to mitigate geopolitical and logistic risks. Consequently, the market is morphing from an early-adopter phase into an operationally complex, clinically driven ecosystem where sustained differentiation will depend on demonstrable clinical impact, scalable operations, and integrated payer engagement.

A strategic analysis of how United States tariff adjustments planned for 2025 are reshaping supply chains, procurement strategies, and manufacturing footprints across the diagnostics ecosystem

The cumulative impact of United States tariff adjustments announced for 2025 introduces a layer of commercial and operational complexity that stakeholders must proactively manage. Tariff measures affecting diagnostic instrumentation, sequencing consumables, and specialized reagents can change landed costs for platform providers and laboratory networks. In response, manufacturers are recalibrating procurement strategies, optimizing bill-of-materials, and engaging in tariff classification reviews to minimize cost disruption while maintaining supply chain continuity.

Beyond immediate price effects, tariffs influence strategic location decisions; some firms accelerate investments in regional manufacturing or assembly to qualify for preferential trade treatment and reduce exposure to cross-border duty burdens. This shift often produces near-term capital expenditure and long-term resilience benefits, but it can also increase unit costs and complicate production planning. Importantly, clinical laboratories and hospital systems that depend on imported equipment may experience compressed gross margins unless manufacturers or distributors absorb or offset tariff-driven increases.

Moreover, tariffs can catalyze innovation in materials science and assay design, prompting efforts to substitute high-duty components with domestically sourced or lower-duty alternatives. Regulatory engagement becomes essential in such transitions, as modifications to hardware or reagent formulations may necessitate device revalidation and dialogue with oversight bodies. In the context of collaborative research and international partnerships, tariff uncertainty reinforces the value of diversified supplier networks and adaptive contracting that incorporate duty-sharing clauses and inventory buffers to sustain uninterrupted clinical services and research continuity.

A comprehensive synthesis of multi-dimensional segmentation revealing how technology, application, biomarker, and end-user distinctions shape product fit and clinical adoption

Segmentation insights reveal how technology choices, clinical applications, biomarker targets, and end-user configurations collectively determine value propositions and adoption pathways for liquid biopsy solutions. Technology segmentation distinguishes digital PCR platforms, which include BEAMing and droplet-based digital PCR variants, from next-generation sequencing approaches that encompass targeted sequencing, whole exome sequencing, and whole genome sequencing, while quantitative PCR remains an accessible option for established assays. Each technological family delivers a distinct balance of sensitivity, throughput, and cost structure, and understanding these trade-offs is critical to matching assay design with clinical intent.

Application segmentation underscores the breadth of clinical use cases, with cancer screening expanding beyond symptomatic diagnosis to include early detection and minimal residual disease monitoring, while infectious disease diagnostics and prenatal testing serve complementary clinical domains; within prenatal testing, approaches address both chromosomal abnormality screening and single gene disorder screening. These application-driven requirements dictate assay sensitivity thresholds, turnaround time expectations, and evidence-generation strategies.

Biomarker segmentation highlights cell-free DNA as a versatile analyte, with circulating tumor DNA representing a disease-specific subset used extensively in oncology, and exosomes offering a rich source of proteomic and nucleic acid signals that may enhance biological resolution. Lastly, end-user segmentation shows diverse operational contexts across commercial laboratories, hospital laboratories, and research institutes, each with distinct procurement models, throughput needs, regulatory pressures, and integration capabilities. Taken together, these intersecting segmentation dimensions guide product roadmaps, reimbursement engagement, and clinical validation strategies.

A geographically informed perspective that explains how regional regulatory frameworks, reimbursement landscapes, and infrastructure maturity determine commercialization trajectories across world markets

Regional dynamics are critical to strategy, with distinct regulatory regimes, reimbursement systems, and healthcare infrastructure influencing how liquid biopsy solutions scale. In the Americas, clinical innovation is often driven by integrated healthcare systems and commercial laboratory networks that enable rapid clinical validation and broad insurance negotiations, while private and public partnerships further advance population screening pilots and oncology care pathways. Europe, the Middle East & Africa present a mosaic of regulatory harmonization efforts and national health technology assessment processes that require tailored evidence packages and localized commercial strategies; centralized regulatory cooperation and regional procurement mechanisms often influence market entry sequencing.

Across Asia-Pacific, diverse healthcare markets range from highly developed precision medicine ecosystems with advanced sequencing adoption to emerging markets where cost-effective, scalable screening solutions are prioritized. Regional manufacturing capacity, digital infrastructure maturity, and local policy incentives for biotechnology investment also shape where companies choose to invest in clinical trials, supply networks, and commercial teams. In all regions, cross-border collaborations and data-sharing frameworks increasingly underpin multicenter studies, enabling comparability and facilitating broader guideline incorporation. Therefore, regional strategies must balance global platform coherence with localized execution to capture clinical and commercial opportunities effectively.

An incisive review of competitive dynamics showing how vertical integration, partnership architectures, and technological differentiation are driving strategic positioning across industry players

Key company insights emphasize strategic positioning, capability integration, and partnership orchestration as primary determinants of competitive advantage. Established instrument manufacturers often leverage installed bases and service networks to accelerate adoption of new assays, whereas sequencing platform providers compete on throughput, error suppression, and ecosystem support such as library kits and cloud-based analytics. Diagnostic kit and reagent suppliers focus on supply-chain reliability and reproducible manufacturing processes, while specialized bioinformatics firms differentiate through proprietary variant calling, multi-analyte fusion algorithms, and clinical reporting workflows that streamline interpretation for end users.

At the same time, innovative start-ups are pursuing narrow clinical niches or integrated service models that combine sample collection, high-sensitivity assays, and longitudinal reporting to address specific clinical gaps such as recurrence monitoring or population-level screening. Collaboration patterns increasingly involve co-development agreements between technology vendors and clinical laboratory networks to accelerate clinical validation and reimbursement dialogues. Consequently, vertical integration-spanning assay chemistry, instrumentation, software, and laboratory services-emerges as a recurring strategic theme, as does the use of strategic equity partnerships and licensing arrangements to expand geographic reach and reduce time-to-market.

Practical and prioritized strategic recommendations designed to help industry leaders align technology development, evidence generation, and commercial execution for sustainable growth

Actionable recommendations for industry leaders focus on aligning product development with clinical need, strengthening supply chain resilience, and prioritizing evidence generation that resonates with payers and guideline bodies. Manufacturers should sequence investments to balance near-term access with long-term platform scalability, adopting modular designs that facilitate component substitution and localization when tariffs or logistics create headwinds. Simultaneously, companies must invest in comprehensive clinical validation programs that demonstrate meaningful clinical utility for targeted indications such as early detection and minimal residual disease, while designing pragmatic trials that reflect routine clinical workflows.

On the commercial side, stakeholders should pursue flexible go-to-market models that combine direct laboratory services, partnerships with hospital systems, and channel distribution to reach different end users. Investment in interoperable analytics and clear clinical reporting standards will lower barriers for adoption among clinicians. Additionally, proactive engagement with payers and health technology assessment agencies to co-develop real-world evidence strategies will accelerate reimbursement discussions. Finally, industry leaders should cultivate collaborative ecosystems-linking technology providers, laboratories, and academic centers-to share data, harmonize standards, and expedite translation from assay innovation to scalable clinical practice.

A transparent and reproducible research framework combining primary stakeholder engagement, peer-reviewed evidence synthesis, and scenario analysis to support robust strategic conclusions

The research methodology integrates multi-source evidence collection, rigorous validation, and iterative synthesis to ensure findings reflect both technological realities and clinical practice. Primary data inputs include structured interviews with laboratory directors, clinical investigators, and industry executives, combined with analysis of peer-reviewed clinical studies, regulatory filings, and conference disclosures to triangulate assay performance and clinical utility. Secondary research complements these insights by mapping technology trajectories, supply-chain configurations, and regional regulatory frameworks to contextualize strategic implications.

Analytical processes involve cross-validation of technical claims against independent performance studies, sensitivity analyses of supply-chain scenarios, and scenario planning to assess the potential effects of policy changes such as tariffs or reimbursement shifts. Throughout, methodological transparency is maintained by documenting inclusion criteria for studies and interview protocols, thereby enabling reproducibility and critical appraisal. Finally, iterative expert review cycles were used to surface divergent perspectives and reconcile them into coherent, actionable conclusions that support decision-making for stakeholders across the diagnostics ecosystem.

A forward-looking synthesis that connects technical maturity, evidence requirements, and operational strategy to the achievable clinical impact of liquid biopsy innovations

In conclusion, non-invasive liquid biopsy stands at an inflection point where technical maturity, evidence accumulation, and evolving commercial models converge to create substantial clinical opportunity. As assay sensitivity and informatics capabilities improve, applications that once seemed speculative are transitioning into realistic clinical pathways, particularly for oncology, infectious disease surveillance, and prenatal screening. Nevertheless, success will require deliberate alignment among technology developers, laboratory operators, payers, and regulators to generate the appropriate evidence, define clinical workflows, and ensure cost-effective deployment.

Moreover, external factors such as trade policy adjustments and regional infrastructure variation will influence operational choices and investment priorities. Organizations that adopt adaptive supply-chain strategies, pursue modular and validated platform designs, and prioritize stakeholder collaboration are most likely to convert technical advantage into durable clinical impact. Ultimately, the ability to translate analytical performance into actionable clinical decisions will determine which solutions achieve broad adoption and drive the next phase of precision diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Non-Invasive Liquid Biopsy Market, by Technology

  • 8.1. Digital PCR
    • 8.1.1. BEAMing
    • 8.1.2. Droplet Digital PCR
  • 8.2. Next Generation Sequencing
    • 8.2.1. Targeted Sequencing
    • 8.2.2. Whole Exome Sequencing
    • 8.2.3. Whole Genome Sequencing
  • 8.3. Quantitative PCR

9. Non-Invasive Liquid Biopsy Market, by Biomarker

  • 9.1. Cell Free DNA
  • 9.2. Circulating Tumor DNA
  • 9.3. Exosomes

10. Non-Invasive Liquid Biopsy Market, by Sample Type

  • 10.1. Stool
  • 10.2. Urine
  • 10.3. Saliva

11. Non-Invasive Liquid Biopsy Market, by Application

  • 11.1. Cancer Screening
    • 11.1.1. Early Detection
    • 11.1.2. Minimal Residual Disease Monitoring
  • 11.2. Infectious Disease Diagnostics
  • 11.3. Prenatal Testing
    • 11.3.1. Chromosomal Abnormality Screening
    • 11.3.2. Single Gene Disorder Screening

12. Non-Invasive Liquid Biopsy Market, by End User

  • 12.1. Commercial Laboratories
  • 12.2. Hospital Laboratories
  • 12.3. Research Institutes

13. Non-Invasive Liquid Biopsy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Non-Invasive Liquid Biopsy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Non-Invasive Liquid Biopsy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Non-Invasive Liquid Biopsy Market

17. China Non-Invasive Liquid Biopsy Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Angle PLC
  • 18.6. Bio-Rad Laboratories, Inc.
  • 18.7. Bio-Techne Corporation
  • 18.8. Biocept, Inc.
  • 18.9. DiaCarta, Inc.
  • 18.10. Epic Sciences Inc.
  • 18.11. F. Hoffmann-La Roche Ltd.
  • 18.12. Grail, Inc.
  • 18.13. Guardant Health, Inc.
  • 18.14. Illumina, Inc.
  • 18.15. Integrated DNA Technologies, Inc.
  • 18.16. Laboratory Corporation of America Holdings
  • 18.17. Lonza Group Ltd.
  • 18.18. Lucence Diagnostics Pte. Ltd.
  • 18.19. LungLife AI, Inc.
  • 18.20. Mdxhealth BV
  • 18.21. MedGenome Labs Ltd.
  • 18.22. Menarini Silicon Biosystems SpA
  • 18.23. Merck KGaA
  • 18.24. Natera, Inc.
  • 18.25. Nonacus Limited
  • 18.26. Norgen Biotek Corporation
  • 18.27. Oasis Diagnostics Corporation
  • 18.28. OraSure Technologies, Inc
  • 18.29. QIAGEN GmbH
  • 18.30. Thermo Fisher Scientific Inc.
  • 18.31. Zymo Research Corp.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BEAMING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BEAMING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BEAMING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DROPLET DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DROPLET DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DROPLET DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CELL FREE DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CELL FREE DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CELL FREE DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY STOOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY STOOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY STOOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CHROMOSOMAL ABNORMALITY SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CHROMOSOMAL ABNORMALITY SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CHROMOSOMAL ABNORMALITY SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SINGLE GENE DISORDER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SINGLE GENE DISORDER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SINGLE GENE DISORDER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 178. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 179. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 180. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 183. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 184. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 208. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 209. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 210. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 213. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 214. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 218. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 219. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 220. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 223. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 224. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)